PE20180656A1 - Derivados de heteroarilo biciclico fusionados con actividad como inhibidores de phd - Google Patents

Derivados de heteroarilo biciclico fusionados con actividad como inhibidores de phd

Info

Publication number
PE20180656A1
PE20180656A1 PE2018000126A PE2018000126A PE20180656A1 PE 20180656 A1 PE20180656 A1 PE 20180656A1 PE 2018000126 A PE2018000126 A PE 2018000126A PE 2018000126 A PE2018000126 A PE 2018000126A PE 20180656 A1 PE20180656 A1 PE 20180656A1
Authority
PE
Peru
Prior art keywords
activity
phd inhibitors
heteroaryl derivatives
derivatives fused
bicycle
Prior art date
Application number
PE2018000126A
Other languages
English (en)
Spanish (es)
Inventor
Saleh Ahmed
Gregory Barker
Hannah Canning
Richard Davenport
David Harrison
Kerry Jenkins
David Livermore
Susanne Wright
Natasha Kinsella
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20180656A1 publication Critical patent/PE20180656A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2018000126A 2015-03-18 2016-03-17 Derivados de heteroarilo biciclico fusionados con actividad como inhibidores de phd PE20180656A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Publications (1)

Publication Number Publication Date
PE20180656A1 true PE20180656A1 (es) 2018-04-17

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000126A PE20180656A1 (es) 2015-03-18 2016-03-17 Derivados de heteroarilo biciclico fusionados con actividad como inhibidores de phd

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (2) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383747B (es) 2016-02-24 2025-03-14 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak)
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
AU2020368368B2 (en) * 2019-10-14 2026-03-19 The Regents Of The University Of California Broad spectrum anti-cancer compounds
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso
CN115413277B (zh) * 2020-04-20 2023-08-01 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
NZ523807A (en) 2000-06-30 2004-09-24 Wyeth Corp Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2011168582A (ja) 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
JPWO2014030716A1 (ja) 2012-08-23 2016-08-08 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
JP2018512408A (ja) 2018-05-17
NZ735631A (en) 2023-07-28
DOP2017000209A (es) 2017-10-15
KR102609431B1 (ko) 2023-12-04
EP3271357A1 (en) 2018-01-24
AU2016234209B2 (en) 2020-08-27
CL2017002354A1 (es) 2018-05-04
CR20170468A (es) 2018-04-27
HK1249512A1 (en) 2018-11-02
IL254277A0 (en) 2017-10-31
WO2016148306A1 (en) 2016-09-22
ECSP17069696A (es) 2018-02-28
SG11201707280VA (en) 2017-10-30
EA035739B1 (ru) 2020-08-03
EP3271357B1 (en) 2019-11-27
IL254277B (en) 2020-10-29
EA201792057A1 (ru) 2018-04-30
DK3271357T3 (da) 2020-02-17
PT3271357T (pt) 2020-02-21
GEP20207095B (en) 2020-04-10
ZA201706612B (en) 2019-01-30
PH12017501699B1 (en) 2023-06-30
ES2774052T3 (es) 2020-07-16
CA2979024A1 (en) 2016-09-22
UA123668C2 (uk) 2021-05-12
KR20170129874A (ko) 2017-11-27
PH12017501699A1 (en) 2018-03-12
MY194873A (en) 2022-12-21
JP6726681B2 (ja) 2020-07-22
US20180072714A1 (en) 2018-03-15
MX2017011902A (es) 2017-12-15
CN107531698B (zh) 2024-08-13
GEAP201914608A (en) 2019-10-10
BR112017019653B1 (pt) 2023-10-03
CA2979024C (en) 2024-02-20
TN2017000384A1 (en) 2019-01-16
AU2016234209A1 (en) 2017-10-12
BR112017019653A2 (pt) 2018-05-15
CN107531698A (zh) 2018-01-02
GB201504565D0 (en) 2015-05-06
US10287286B2 (en) 2019-05-14
CO2017009353A2 (es) 2017-11-30
HUE047918T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
ECSP16074478A (es) Compuestos novedosos
CU20180073A7 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
MX2017017008A (es) Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CL2015002060A1 (es) Compuestos.
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
ECSP18056196A (es) Derivados de indano
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos